Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Chicago at the SACHS 9th Annual Immuno-Oncology Innovation Forum, June 2, and the ASCO (American Society of Clinical Oncology) annual meeting, June 2 – 6. They will be connecting with investors and clinical experts to discuss how Immunophotonics continues to explore the ability of IP-001 to transform a routine interventional-oncology procedure into a systemic immunotherapy against cancer.
